Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | RIPK1 | Q13546 | 3/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.39 |
| ▸ | DPP4 | P27487 | 3/20 | 0.38 |
| ▸ | PREP | P48147 | 1/20 | 0.36 |
| ▸ | FAP | Q12884 | 1/20 | 0.36 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.35 |
| ▸ | NAMPT | P43490 | 1/20 | 0.35 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.34 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10429483 | 0.95 | AKR1C3 (0.43) | POLBL3MBTL1RIPK1LMNACYP2C19 | |
| SCHEMBL25587591 | 0.90 | RIPK1 (0.43) | POLBL3MBTL1RIPK1LMNACYP2C19 | |
| SCHEMBL25587593 | 0.90 | RIPK1 (0.43) | POLBL3MBTL1RIPK1LMNACYP2C19 | |
| SCHEMBL10223175 | 0.86 | POLB (0.63) | POLBL3MBTL1RIPK1LMNACYP2C19 | |
| SCHEMBL13721603 | 0.86 | POLB (0.63) | POLBL3MBTL1RIPK1LMNACYP2C19 | |
| SCHEMBL12788615 | 0.86 | POLB (0.63) | POLBL3MBTL1RIPK1LMNACYP2C19 | |
| SCHEMBL10223176 | 0.82 | RIPK1 (0.47) | POLBL3MBTL1RIPK1LMNACYP2C19 | |
| SCHEMBL19396391 | 0.81 | RIPK1 (0.44) | POLBL3MBTL1RIPK1LMNACYP2C19 | |
| SCHEMBL6961839 | 0.81 | POLB (0.56) | POLBL3MBTL1RIPK1LMNACYP2C19 | |
| SCHEMBL15978914 | 0.81 | RIPK1 (0.46) | POLBL3MBTL1RIPK1LMNACYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9895412-B2 | Cyclic depsipeptide compounds and their uses | CYPRALIS LIMITED (GB) | 2018-02-20 | — | — | US | disclosed |
| US-20170007664-A1 | CYCLIC DEPSIPEPTIDE COMPOUNDS AND THEIR USES | CYPRALIS LIMITED (GB) | 2017-01-12 | — | — | US | disclosed |
| US-20170007664-A1 | CYCLIC DEPSIPEPTIDE COMPOUNDS AND THEIR USES | CYPRALIS LIMITED (GB) | 2017-01-12 | — | — | US | disclosed |
| US-9382295-B2 | Cyclic depsipeptide compounds and their uses | CYPRALIS LIMITED (GB) | 2016-07-05 | — | — | US | disclosed |
| US-9382295-B2 | Cyclic depsipeptide compounds and their uses | CYPRALIS LIMITED (GB) | 2016-07-05 | — | — | US | disclosed |
| US-20150259386-A1 | CYCLIC DEPSIPEPTIDE COMPOUNDS AND THEIR USES | CYPRALIS LIMITED (GB) | 2015-09-17 | — | — | US | disclosed |
| US-20150259386-A1 | CYCLIC DEPSIPEPTIDE COMPOUNDS AND THEIR USES | CYPRALIS LIMITED (GB) | 2015-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170007664-A1 | CYCLIC DEPSIPEPTIDE COMPOUNDS AND THEIR USES | FKBP14, FKBP1A, PIN1 | POLB 3674/4885L3MBTL1 3872/4885RIPK1 1193/4885 |
| US-20150259386-A1 | CYCLIC DEPSIPEPTIDE COMPOUNDS AND THEIR USES | FKBP14, FKBP1A, PIN1 | POLB 3674/4885L3MBTL1 3872/4885RIPK1 1193/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.